Metabolic control by insulin detemir in basal‐bolus therapy: treat‐to‐target study in children and adolescents with type 1 diabetes

ConclusionSince twice‐daily determir showed no clinical advantage over once‐daily detemir, it appears reasonable to commence all children on once‐daily detemir, taking into consideration that younger children and those in active puberty may require twice‐daily therapy (ClinicalTrials.gov number, NCT00542399).

Source: Pediatric Diabetes - January 4, 2013 Category: Endocrinology Authors: Revital Nimri, Yael Lebenthal, Shlomit Shalitin, Hadasa Benzaquen, Sharon Demol, Moshe Phillip Tags: Original Article Source Type: research